Seer Inc Dossier
|
SectorHealth Care IndustryLife Sciences Tools & Services Beta (adjusted)1.33 Intrinsic Value $2.13median of 2 methodsbased on filings through 30 Jun 2026 Market Price $2.20Price as of 1 Oct 2026 Near fair valueIntrinsic value is 3% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $121.8M Enterprise Value $95.7M Shares Outstanding 55.4M diluted Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Seer, Inc. is a pioneer in deep, unbiased proteomics, utilizing its proprietary Proteograph Product Suite to enable large-scale biological insights. However, the company is currently navigating a challenging commercial transition characterized by declining year-over-year revenues, macroeconomic headwinds in academic and government funding, and competitive pressures. While Seer maintains a robust balance sheet with over $219 million in cash and investments, it is facing an active proxy contest and unsolicited takeover bids from activist investors Bradley L. Radoff and Michael Torok. The board has rejected these bids as value-destructive, emphasizing long-term standalone growth. Given the near-term commercial uncertainty balanced by a strong cash cushion and potential downside protection from acquisition interest, a Hold recommendation is warranted. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$4.00 Mean target$4.00 High · most bullish analyst$4.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $1.2720% The bear case involves prolonged commercial stagnation, further revenue declines, and high cash burn that erodes the company's balance sheet strength. Additionally, a disruptive proxy contest could lead to management instability and strategic misalignment. Base CaseCentral scenario $2.4050% The base case assumes Seer continues its standalone strategy, maintaining tight cost discipline to narrow operating losses while slowly expanding its customer base. Revenue remains volatile in the near term as academic funding headwinds persist, and the stock trades close to its cash value. Bull CaseUpside scenario $4.0030% The bull case is driven by a successful commercial turnaround under the new Chief Commercial Officer, rapid adoption of the Proteograph ONE assay and SP200 automation, and a potential premium acquisition by a strategic buyer or the activist group at a level that fully values the company's technology and cash reserves. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |